Photo by Natali_Mis/iStock via Getty Images
In my first article, I compared Mirum Pharma (MIRM) with Albireo Pharma (ALBO) and concluded that Albireo must be valued higher than Mirum. Nevertheless, both companies are significantly undervalued. In my opinion, this is especially caused by the expected fierce battle for market share between the two companies. Both companies have a similar drug targeting the same indications. Each company is trying to get approval first and possibly secure exclusivity…

Click here to view the original article.